Loading company…
Tome Biosciences develops programmable gene insertion technology for genomic therapeutics.
Tome Biosciences develops gene insertion technology using CRISPR for cell and genome engineering. Its platform is designed to insert genetic sequences into genomes, and the company is developing genomic therapeutics. Founded in 2021, it is based in Watertown, US, and was co-founded by Omar Abudayyeh and Jonathan Gootenberg. In December 2023, it raised USD 213 million in Series A and B funding from Andreessen Horowitz, ARCH Venture Partners, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, and Alexandria Venture Investments.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in